在hERG基因的新型突变与阿齐思罗米诱导的长QT综合征相关
Yun-Jiu Cheng1,2, Yang Wu3,4, Hui-Qiang Wei1
1Department of Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Molecular biology reports
|April 16, 2024
概括
一种新型的人类以太-to-go-go相关基因 (hERG) 突变,I1025N,与阿齐思罗米结合,损害了hERG通道的成熟和功能,导致获得的长QT综合征 (LQTS). 这表明对药物诱导的LQTS有遗传敏感性.
科学领域:
- 心血管药理学心血管药理学
- 分子心脏病学分子心脏病学
- 离子通道生理学 离子通道生理学
背景情况:
- 人类以太-to-go-go相关基因 (hERG) 的突变与长QT综合征 (LQTS) 有关.
- 已知宏类抗生素,如阿齐思罗米,会增加心血管疾病的风险.
- 获得的LQTS的机制,特别是对宏类物质的反应,尚未完全理解.
研究的目的:
- 研究一种新型hERG突变 (I1025N) 在阿兹胺诱导的长QT综合征 (LQTS) 中的作用.
- 阐明I1025N突变和阿齐思罗米对hERG通道功能和表达的联合影响.
主要方法:
- 桑格测序确定了一名患有亚齐胺诱导获得的LQTS的患者的I1025NhERG突变.
- 表达突变I1025NhERG等离子体的HEK-293细胞被治疗了阿齐思罗米.
- 西部斑点,免疫光学和电生理学评估了hERG蛋白的表达,成熟和通道电流.
主要成果:
- I1025N突变导致成熟hERG蛋白减少,不成熟蛋白增加.
- 阿兹罗米辛对hERG蛋白质的成熟产生了负面影响,并以剂量依赖的方式抑制了hERG通道电流.
- I1025N突变和阿齐思罗米协同减少了hERG通道表达和电流,而不影响通道门.
结论:
- hERG基因突变可能会导致阿齐思罗米诱导的获得LQTS的遗传易感性.
- 该研究强调了LQTS病变发生过程中遗传倾向和药物效应之间的潜在相互作用.
- 了解这些机制对于管理与类抗生素相关的心血管风险至关重要.
相关概念视频
02:32Exon Recombination
3.1K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon...
Exon shuffling follows “splice frame rules.” Each exon...
3.1K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805